Related references
Note: Only part of the references are listed.Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
P. M. Forde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D. Hellmann et al.
LANCET ONCOLOGY (2017)
Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer
Nobuyuki Katakami et al.
LUNG CANCER (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Preliminary results from the international neoadjuvant melanoma consortium (INMC).
Alexander M. Menzies et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses
Yonit Lavin et al.
CELL (2017)
Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer
A. Blythe Ryerson et al.
CANCER (2016)
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer
Suresh Senan et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer
Matthew J. Boyer et al.
LUNG CANCER (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Jing Liu et al.
CANCER DISCOVERY (2016)
A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533
Antoinette J. Wozniak et al.
CLINICAL LUNG CANCER (2015)
Cisplatin and Etoposide Versus Carboplatin and Paclitaxel With Concurrent Radiotherapy for Stage III Non-Small-Cell Lung Cancer: An Analysis of Veterans Health Administration Data
Rafael Santana-Davila et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non-Small-Cell Lung Cancer
Elyn H. Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
Jeffrey D. Bradley et al.
LANCET ONCOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Exploiting the immunomodulatory properties of chemotherapeutic drugs to improve the success of cancer immunotherapy
Kelly Kersten et al.
FRONTIERS IN IMMUNOLOGY (2015)
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Simon J. Dovedi et al.
CANCER RESEARCH (2014)
Enhanced Cancer Radiotherapy through Immunosuppressive Stromal Cell Destruction in Tumors
Chao-Yi Wu et al.
CLINICAL CANCER RESEARCH (2014)
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
Charles Butts et al.
LANCET ONCOLOGY (2014)
Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer
Nicole Ezer et al.
RADIOTHERAPY AND ONCOLOGY (2014)
Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410
Walter J. Curran et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
Kathy S. Albain et al.
LANCET (2009)
Systemic effects of local radiotherapy
Silvia C. Formenti et al.
LANCET ONCOLOGY (2009)
Enhancement of antitumor radiation efficacy and consistent induction of the abscopal effect in mice by ECI301, an active variant of macrophage inflammatory protein-1α
Kenshiro Shiraishi et al.
CLINICAL CANCER RESEARCH (2008)
Impact of postoperative radiation therapy on survival in patients with complete resection and Stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: The Adjuvant Navelbine International Trialist Association (ANITA) randomized trial
Jean-Yves Douillard et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023
Karen Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Treatment of non-small cell lung cancer stage I and stage II - ACCP evidence-based clinical practice guidelines (2nd edition)
Walter J. Scott et al.
CHEST (2007)
The IASLC lung cancer staging project: Proposals for the revision of he TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours
Peter Goldstraw et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer
John Nemunaitis et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: A phase II Southwest Oncology Group study (S9504)
David R. Gandara et al.
CLINICAL LUNG CANCER (2006)
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
Eric A. Reits et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
S Demaria et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer
T Le Chevalier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy
M Chakraborty et al.
JOURNAL OF IMMUNOLOGY (2003)
Share Paper
